Glenmark Pharmaceutical gets USFDA nod for psoriasis spray

The US-based Pharmaceuticals Glenmark has confirmed to have received the final nod from US health regulator for its Clobetasol Propionate spray used for the treatment of moderate to severe plaque psoriasis in adults.

Glenmark Pharmaceuticals received approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate spray 0.05 percent, the company said in a statement.

The product is a generic version of Galderma Laboratories L P's Clobex spray in the same strength, it added.

This product will be manufactured at the Glenmark's Baddi plant in Himachal Pradesh.

"As per IQVIA sales data for the 12 month period ending January 2018, the Clobex spray, 0.05 percent market that includes brand and all available therapeutic equivalents achieved annual sales of approximately USD 30.5 million," it said.

The company's portfolio consists of 131 products authorised for distribution in the US market and 63 ANDA's pending approval with the USFDA.

The company's stock was trading 0.12 per cent up at Rs 539.95 on BSE.